ClinicalTrials.gg
CompletedNCT05199610Updated Apr 19, 2023

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

A Phase 1 interventional study of aumolertinib in Severe Hepatic Impairment, sponsored by EQRx International, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by EQRx International, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Participants aged 18 to 75 years with severe hepatic impairment (Child-Pugh class C) who meet the full study eligibility criteria will be enrolled into the study. For each participant with severe hepatic impairment, a corresponding healthy participant will be enrolled who matches with regard to age, sex, and BMI. A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments. The study will measure and describe the concentrations of EQ143 and its metabolite (HAS-719) in plasma over the course of 9 days (including calculation of PK parameters), the degree of EQ143 and metabolite HAS-719 (and other metabolites, if applicable) binding to proteins in plasma, and the safety of administering a single dose of EQ143 in severely hepatically impaired and matched healthy participants

02

Conditions studied

  • Severe Hepatic Impairment
03

In context

Lead sponsor

EQRx International, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Main Criteria for Inclusion: All Participants

  1. Must be willing to participate in the study and sign the form (ICF).
  2. Must be willing and able to complete all study-specific procedures and visits.
  3. Is 18 to 75 years of age, inclusive, at Screening.
  4. Is able to take and swallow oral medication.
  5. of 18.0 to 42.0 kg/m2
  6. High probability for compliance with and completion of the study, in the opinion of the Investigator.
  7. Must meet all of the applicable requirements for pregnancy and , as follows:

    1. If female:

      • Is a female participant of who:

        • Has a negative serum pregnancy test result within 48 hours before Day -1;
        • Is not breastfeeding;
        • Agrees to use highly effective contraceptive measures during heterosexual intercourse throughout the study and for 12 weeks following EQ143 administration; AND
        • Agrees not to donate ova for the same time period; OR
      • Is a participant of non-childbearing potential, as confirmed by meeting both of the following criteria:

        • Has a negative serum or urine pregnancy test result within 48 hours before Day -1; AND is confirmed by the Investigator to be medically per one or more of the following parameters:

          • Age, in addition to any of the other parameters listed here;
          • Menses status (absence of menses for ≥ 1 year); or

            • Surgical status (prior hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), with participant providing documentation of the surgical sterilization procedure (by operative report or ultrasound scan) prior to EQ143 administration; or
            • Follicle-stimulating hormone (FSH) level.
    2. If male:

      • Agrees to use a highly effective method of contraception (eg, male condom in addition to hormonal contraception) during heterosexual intercourse throughout the study and for 12 weeks following EQ143 administration; AND
      • Agrees to refrain from donating sperm for the same time period. Note: For all study participants, contraceptive use must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    Main Criteria for Inclusion: Hepatically Impaired Participants

  8. Severe hepatic impairment ( class C according to the Child-Pugh classification).

    Notes:

    • Severe hepatic impairment is confirmed and documented based on at least one of the following: medical history, physical examination, computed axial tomography scan, magnetic resonance imaging and/or liver .
    • Screening laboratory test results for serum ; serum albumin; either (aPTT) or prothrombin time (PT) (at site discretion); and stage of hepatic encephalopathy (with or without ascites) are consistent with Child-Pugh class C.
    • Hepatic impairment etiology should be one of the following: chronic alcoholism; chronic viral hepatitis; nonalcoholic steatohepatitis; hepatitis; Wilson disease; alpha-1 antitrypsin deficiency; glycogen storage diseases; galactosemia; or cryptogenic.
  9. If participant has concurrent stable medical condition(s) in addition to hepatic impairment-eg, diabetes without renal complications-the Investigator, Medical Monitor, and Sponsor Clinical Pharmacologist collectively agree that the condition(s) will not introduce an additional risk factor for the participant or interfere with the participant's ability to meet the study requirements.
  10. If participant is taking medication(s) necessary for the management of their hepatic disease, and/or of concomitant stable medical conditions the medication regimen has been stable for at least 7 days before EQ143 administration and the Medical Monitor and Sponsor Clinical Pharmacologist agree that the medication is not expected to interfere with the PK of EQ143.

    Main Criteria for Inclusion: Healthy Matched Participants

  11. Normal renal function, defined as calculated ≥ 60 mL/min (as estimated by Cockroft-Gault equation).
  12. Normal hepatic function, defined as total bilirubin ≤ 1.2 mg/dL and not meeting any Child-Pugh classification criteria
  13. Healthy, as determined by the Investigator on the basis of medical history; physical examination; clinical laboratory test results; vital sign measurements; and 12-lead (ECG).
  14. Matched to the hepatically impaired participants in sex, age (± 10 years), and BMI (± 20% of BMI at Screening).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Main Criteria for Exclusion: All Medical History

  1. Family history of , syncope, seizure, or unexplained cardiac-related death.
  2. Presence or history of any disorder that may prevent the successful completion of the study.
  3. Current or recent (within 3 months of Day 1 of the study) gastrointestinal disease that could impact the absorption of EQ143.
  4. History of drug abuse within 1 year before Day 1 of the study
  5. Is a regular smoker (ie, smokes more than 5 cigarettes per day or more than 10 packets per year), and is not willing to refrain from smoking from 48 hours before EQ143 administration through the final study visit.

    Allergies and Adverse Drug Reactions

  6. History of any drug allergy or adverse drug reaction. Physical and Laboratory Findings
  7. Plasma potassium and/or magnesium values outside the normal range.

    • Note: At the discretion of the Investigator, these tests may be repeated to confirm a result that is outside the normal range; repeat test results must be within normal limits to confirm participant eligibility.
  8. An automatic absolute QT interval with Fridericia's correction (QTcF) reading at Screening of > 480 ms (males) or > 500 ms (females).
  9. Has evidence of active bacterial, fungal, or viral infection (including [HIV] or SARS-CoV-2, as detailed below) which would preclude safe enrollment as assessed by the treating Investigator.

    • Note regarding HIV: Participants with positive serologic finding and detectable HIV are excluded; however, participants with undetectable HIV and a viral load of 0 are not excluded if meeting all other eligibility criteria.
    • Note regarding SARS-CoV-2: The study SARS-CoV-2 requirements are determined by institutional standards (and local/country regulations, as applicable).

      • At Investigator discretion, any participant who tests positive and/or is symptomatic for SARS-CoV-2 during Screening may either be excluded from the study or delay enrollment until active infection has been excluded per institutional standards.
      • During the study, any SARS-CoV-2 testing is to be performed as clinically indicated for the individual participant. The Investigator must document the results of all tests performed. Any confirmed infection is to be recorded as an AE or, in the event that clinical manifestation warrants such, recorded and handled as an SAE as detailed.
  10. Positive finding on urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cocaine, opiates), except a) cannabinoids or b) substances that are not prohibited per protocol and are legally prescribed to the participant, and have therefore been documented as concomitant medications (with additional considerations as noted below).

    • Note: Any participant who is taking any prescribed substance that triggers a positive urine drug screen result must have potential drug abuse ruled out by the Investigator. Additionally, any such participant must be confirmed by the Investigator to meet all other study eligibility criteria to rule out any potential excluded comorbidities associated with the prescribed substance.

    Prohibited Treatments

  11. Consumption of alcoholic beverages from 24 hours before Day 1 of the study through the final study visit.
  12. Consumption of grapefruit or grapefruit-containing products from 72 hours before Day 1 of the study through the final study visit.
  13. Donation of blood within 30 days before Day 1 of the study.
  14. Involvement in another study of any type within 30 days before EQ143 administration

    Main Criteria for Exclusion: Hepatically Impaired Participants Medical History

  15. Evidence of uncontrolled and clinically significant disease other than impaired hepatic function (eg, cardiovascular, gastrointestinal, cerebrovascular, respiratory, or renal disease, or any other comorbidity that, in the judgment of the Investigator, precludes participation in the study).
  16. Has received, or is currently waiting for, an organ transplant.
  17. Recent history or presence of any disorder that may interfere with the absorption, distribution, metabolism, or excretion of EQ143 (except those conditions associated with the hepatic disease) that may place the participant at risk during participation in the study, as assessed by the treating Investigator.
  18. Presence of surgically created or transjugular intrahepatic portal systemic shunt.

    Physical and Laboratory Findings

  19. Evidence of severe hepatorenal syndrome, as shown by calculated \< 40 mL/min (Cockroft-Gault equation).
  20. Unstable liver disease, as shown by any of these factors/parameters:

    • Spontaneous bacterial peritonitis within 3 months before Day 1 of the study
    • Variceal bleeding within 1 month before Day 1 of the study
    • Severe hyponatremia (sodium level \< 125 mmol/L)
    • Current evidence of hepatocellular cancer
    • Acute hepatic disease caused by an infection or drug toxicity
    • Severe encephalopathy (Grade 3-4 [ classification) unless at the time of Screening, it is controlled according to local standard of care (including ongoing treatment with lactulose)
    • Presence of severe ascites or severe edema that precludes participation in the study, as judged by the Investigator
    • level ≤ 9.0 g/dL
    • count \< 30 × 109/L for Child-Pugh class C participants
    • Total level > 9 mg/dL
    • Relative increase of or PT by > 50% within the 2 weeks before EQ143 administration
    • Positive serologic findings for surface antigen (HBsAg) and/or virus (HCV) antibodies
    • Note: Test outcomes that are reactive to HCV antibody will be followed by an HCV ribonucleic acid (RNA) test (polymerase chain reaction [PCR]). Participants whose follow-up HCV RNA test (PCR) is reactive will be excluded.

    Prohibited Treatments

  21. Prescription and over-the-counter (OTC) medication that is not taken according to a stable regimen for 7 days before EQ143 administration.
  22. Use of any treatment known to be a strong inhibitor or inducer within approximately 30 days or 5 half-lives, whichever is longer, before Day 1, with the exception of grapefruit or grapefruit-containing products (which are prohibited within 72 hours before Day 1 of the study, as noted above in Exclusion Criterion #12).
  23. Use of any treatment known to be a sensitive CYP3A4 substrate within approximately 4 days (or 5 half-lives, whichever is longer) before and 4 days (or 5 half-lives, whichever is longer) after EQ143 administration.
  24. Concomitant use of medications known to prolong the QTc interval.
  25. Medications that alter gastric pH (eg, proton-pump inhibitors) within 3 days before and 2 days after EQ143 administration.

    Main Criteria for Exclusion: Healthy Matched Participants Medical History

  26. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
  27. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of EQ143.
  28. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before Day 1 of the study.
  29. . History of alcoholism within 1 year before Day 1 of the study, or consumption of more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL glass of aperitif; 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g).

    Physical and Laboratory Findings

  30. Any clinically significant findings on physical examination, vital sign measurements, 12-lead ECGs, or clinical laboratory test results.
  31. Positive serologic findings for HBsAg and/or HCV antibodies.

    • Note: Test outcomes that are reactive to HCV antibody will be followed by an HCV RNA test (PCR). Participants whose follow-up HCV RNA test (PCR) is reactive will be excluded.

    Prohibited Treatments

  32. Use of any prescription drug within 30 days or 5 half-lives, whichever is longer, before EQ143 administration, except hormone replacement therapy in female participants or treatments permitted in consultation with the Medical Monitor.
  33. Use of any OTC drugs, including herbal supplements, within 14 days before Day 1 of the study, except for the occasional use of acetaminophen (paracetamol) and vitamins (≤ 100% of the recommended daily allowance).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Aumolertinib

    single dose oral 55mg of aumolertinib

    Drug: aumolertinib

Interventions

  • A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.

    Also known as: HS-10296

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Cmax of EQ143

    Cmax is defined as the maximum observed concentration of drug

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  2. PK Parameter: AUC0-t of EQ143

    AUC0-t is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  3. PK Parameter: AUCinf of EQ143

    AUCinf is defined as the area under the concentration versus time curve extrapolated to infinite time

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  4. PK Parameter: CL/F of EQ143

    CL/F is defined as apparent clearance

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  5. PK Parameter: Cmax of metabolite, HAS719

    Cmax is defined as the maximum observed concentration of drug

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  6. PK Parameter: AUC0-t of metabolite, HAS719

    AUC0-t is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  7. PK Parameter: AUCinf of metabolite, HAS719

    AUCinf is defined as the area under the concentration versus time curve extrapolated to infinite time

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

Secondary outcomes

  1. Number of Participants with Adverse Event

    Safety will be monitored by vital signs, electrocardiography, and clinical laboratory results

    Time frame: up to 38 Days

  2. PK Parameter of EQ143: Time to peak concentration (tmax)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  3. PK Parameter of EQ143: elimination half-life (t1/2z)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  4. PK Parameter of EQ143: apparent volume of distribution (Vz/F)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  5. PK Parameter of EQ143: fraction unbound (fu)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  6. PK Parameter of EQ143: unbound peak concentration (Cmaxu)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  7. PK Parameter of EQ143: unbound AUC0-t (AUC0-t U)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  8. PK Parameter of EQ143: unbound apparent clearance (CLu/F)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  9. PK Parameter of metabolite, HAS719: Time to peak concentration (tmax)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  10. PK Parameter of metabolite, HAS719: elimination half-life (t1/2z)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  11. PK Parameter of metabolite, HAS719: apparent volume of distribution (Vz/F)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  12. PK Parameter of metabolite, HAS719: fraction unbound (fu)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  13. PK Parameter of metabolite, HAS719: unbound peak concentration (Cmaxu)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  14. PK Parameter of metabolite, HAS719: unbound AUC0-t (AUC0-t U)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

  15. PK Parameter of metabolite, HAS719: unbound apparent clearance (CLu/F)

    Time frame: Predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose

07

Study locations

3 sites
  • American Institute Research
    Los Angeles, California 90017, United States
  • Global Clinical Professionals
    Saint Petersburg, Florida 33705, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Apr 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2021
First posted
Jan 20, 2022
StartActual
Mar 30, 2022
Primary completionActual
Apr 1, 2023
CompletionActual
Apr 1, 2023
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05199610
Lead sponsor
EQRx International, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Mar 30, 2022
Primary completion
Apr 1, 2023
Completion
Apr 1, 2023
Last update
Apr 19, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion